Medpage Today on MSN4d
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Medpage Today on MSN5d
Managing Primary Biliary Cholangitis Progression and Symptoms
Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
GSK's linerixibat meets primary endpoint
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
Pharmabiz58m
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Monthly Prescribing Reference6d
FDA Denies Full Approval of Obeticholic Acid for Primary Biliary Cholangitis
The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.
PoliticsHome7d
Turning ambition into action: improving care for women with primary biliary cholangitis
Primary biliary cholangitis (PBC) may be rare, but its impact on women can be profound, leaving too many undiagnosed for ...
Business Insider1d
GSK announces phase III trial of linerixibat met primary endpoint
in adults with cholestatic pruritus associated with primary biliary cholangitis, a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat resulting in an improvement in itch ...